The conversation is about the effectiveness of using less than 20mg of RU58841, specifically 12.5mg, for hair loss treatment. People are discussing their experiences with different dosages of RU58841.
The user is seeking advice on which treatment to add to their current regimen for male pattern baldness. They have previously tried Dutasteride, Nizoral, and oral Minoxidil, but experienced continued hair loss. They are specifically asking for experiences with RU58841, Stemoxydine, or Alfatradiol.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.
The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.
The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.
Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.
A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.
Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.
RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.
The user shared their 4-year hair regrowth journey using finasteride, minoxidil, RU58841, microneedling, and Nizoral shampoo. They plan to adjust their RU58841 dosage and are considering a hair transplant if current methods don't yield desired results.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.
A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.
A 35-year-old male experienced significant hair improvement using microneedling, finasteride, minoxidil, and keto shampoo. He adjusted his microneedling routine for better results.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.
The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.